Mammary Cell News 11.11 March 28, 2019 | |
| |
TOP STORYAberrant FGFR Signaling Mediates Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor lucitanib. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Atypical Plant Homeodomain of UBR7 Functions as an H2BK120Ub Ligase and Breast Tumor Suppressor The authors demonstrated that the plant homeodomain (PHD) finger of ubiquitin protein ligase e3 component n-recognin7 (UBR7) harbors E3 ubiquitin ligase activity toward monoubiquitination of histone H2B at lysine120 (H2BK120Ub). Purified PHD finger or full-length UBR7 monoubiquitinated H2BK120 in vitro, and loss of UBR7 drastically reduced H2BK120Ub genome-wide binding sites in MCF10A cells. [Nat Commun] Full Article BRCA1/BARD1-Dependent Ubiquitination of NF2 Regulates Hippo-YAP1 Signaling Researchers showed that BRCA1 facilitated stabilization of YAP1 protein and turning “off” the Hippo pathway through ubiquitination of NF2. In BRCA1-deficient cells the Hippo pathway was “turned on.” [Proc Natl Acad Sci USA] Abstract Acquisition of a Hybrid E/M State Is Essential for Tumorigenicity of Basal Breast Cancer Cells Using the recently described CD104+/CD44hi antigen marker combination, scientists isolated highly tumorigenic breast cancer cells residing stably—both in vitro and in vivo—in an intermediate phenotypic state and coexpressing both epithelial and mesenchymal markers. [Proc Natl Acad Sci USA] Full Article FGFR4 Phosphorylates MST1 to Confer Breast Cancer Cells Resistance to MST1/2-Dependent Apoptosis Using a kinase substrate screen, investigators identified mammalian sterile20-like kinase (MST)1 and MST2 among the top substrates for fibroblast growth factor receptor 4 (FGFR4). In COS-1 cells, MST1 was phosphorylated at Y433 residue in an FGFR4 kinase activity-dependent manner, as assessed by mass spectrometry. [Cell Death Differ] Full Article Researchers showed that TIS11b was markedly underexpressed in three breast cancer cell lines, as well as in breast tumor samples. They hypothesized that restoring intracellular TIS11b levels could impair cancer cell phenotypic traits. [Oncogene] Abstract Scientists overexpressed glycoprotein Nmb (GPNMB) in the mammary epithelium to generate MMTV/GPNMB transgenic mice and crossed these animals to the MMTV/Wnt-1 mouse model, which is known to recapitulate features of human basal breast cancers. [Oncogene] Abstract Deciphering the Mammary Stem Cell Niche: A Role for Laminin-Binding Integrins Investigators found that stem cell activity, as evaluated in transplantation and mammosphere assays, was reduced in mammary basal cells depleted of laminin receptors containing α3- and α6-integrin subunits. [Stem Cell Reports] Full Article Using quantitative readouts of signaling pathway activation and cell proliferation, the authors examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. [Breast Cancer Res] Full Article Inhibition of USP2 Eliminates Cancer Stem Cells and Enhances TNBC Responsiveness to Chemotherapy Investigators identified that USP2 deubiquitinating enzyme was upregulated in cancer stem cells (CSCs) and was a novel regulator of CSCs. Genetic and pharmacological targeting of USP2 substantially inhibited the self-renewal, expansion and chemoresistance of CSCs. [Cell Death Dis] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSMALAT1 Long Non-Coding RNA and Breast Cancer The authors discuss the literature that support a pro-tumorigenic role for metastasis associated lung adenocarcinoma transcript 1 MALAT1 in order to gain potential insights into the basis of these observed differences. [RNA Biol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSBriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® BriaCell Therapeutics Corp. announced it is finalizing the analysis of the initial efficacy data of the first six patients in the combination study of its lead candidate, Bria-IMT™, with pembrolizumab in advanced breast cancer. [Press release from BriaCell Therapeutics Corp. discussing research to be presented at the American Association for Cancer Research (AACR) Annual Meeting, Atlanta] Press Release | |
| |
INDUSTRY NEWSOdonate Therapeutics Initiates CONTESSA TRIO Odonate Therapeutics, Inc. announced the initiation of CONTESSA TRIO, a multi-cohort, multicenter, Phase II study of tesetaxel, Odonate’s investigational, orally administered taxane. [Odonate Therapeutics, Inc.] Press Release Puma Biotechnology, Inc. announced that the FDA has approved NERLYNX™, formerly known as PB272, a once-daily oral tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. [Puma Biotechnology, Inc.] Press Release Atossa Genetics Inc. announced that the Institutional Review Board (IRB) has approved the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive breast cancer patient. This IRB approval follows the FDA’s recent “safe to proceed” letter and permits Atossa’s oral Endoxifen to be provided to the patient. [Atossa Genetics Inc.] Press Release | |
| |
POLICY NEWSNIH May Bar Peer Reviewers Accused of Sexual Harassment The National Institutes of Health (NIH) in Bethesda, Maryland, reminded the research community this week that the agency can—and sometimes does—bar scientists accused of sexual harassment from serving as peer reviewers. [ScienceInsider] Editorial Top US Institutes Still Aren’t Reporting Clinical-Trial Results on Time Many leading US universities are breaking the law by failing to make public the results of clinical trials. A report found that 25 of the 40 universities that sponsor the most trials in the United States did not post study results on a public, government register within 12 months of completion, as is required by US law. [Nature News] Editorial As Elsevier Falters, Wiley Succeeds in Open-Access Deal Making Over the last few years, Project DEAL, a consortium that represents around 700 academic institutions in Germany, has been in negotiations for nationwide licensing agreements with three of the largest scholarly publishers—Elsevier, Springer Nature, and Wiley. [The Scientist] Editorial
| |
EVENTSNEW AACR International Conference New Horizons in Cancer Research Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellowship – Breast Cancer Research (Washington University School of Medicine) Postdoctoral Position – Breast Cell Atlas (University of Cambridge) Professor – Breast Cancer (University Hospitals Cleveland Medical Center) Postdoctoral Researcher – BRCA1/2-Deficient Tumors (University of Oxford) Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory) Scientific Review Officer – Breast Cancer (METAvivor) Faculty Position – Breast Cancer Research (The Mayo Clinic) Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA) Postdoctoral Fellowship – Breast Cancer (Providence John Wayne Cancer Institute) Postdoctoral Fellow – Breast Cancer Research (City of Hope) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|